Navigation Links
InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Date:9/29/2008

uebec 2008

BioContactQuebec 2008 is a biopharmaceutical partnership symposium gathering over 1200 participants and more than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, immunology and inflammation.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
2. InNexus Biotechnology Strengthens Patent Team With New Leadership
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
8. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
9. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
10. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
11. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DIEGO , March 3, 2015  Halozyme Therapeutics, Inc. ... Barclays 2015 Global Healthcare Conference in Miami, FL ... a.m. PT. David A. Ramsay , Chief Financial Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has announced ... - 2025" report to their offering. ... extensive study on the marketed and pipeline gene therapies. ... this field for over a decade but there are ... one approved in the EU). There are many promising ...
(Date:3/3/2015)... BlueInGreen announces the addition ... network. The business venture will bring the world’s ... Provinces, exclusively through Resource Systems. , Since 1986, ... premiere manufacturing representative firms, hosting a diverse portfolio ... wastewater markets. More information on Resource Systems is ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The winners ... excellence were honored by the Global Supply Chain ... which took place on Wednesday, February 25th, 2015, at ... GSCRC was formed to bring together supply chain risk ... to advance the professional discipline through opportunities to collaborate, ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4
... ... that Maastricht based forensics lab DNalysis have successfully rolled out PatentSafe, protecting their forensic ... electronic repository. , ... Bracknell, UK (PRWEB) Feburary 10, 2010 -- Amphora Research Systems is pleased to announce ...
... , , , , , , , , , ... 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" ... and China , announced,today that it priced a public offering ... share. Net proceeds from the offering, after underwriting,discounts and commissions and ...
... , , ... 11 /PRNewswire-Asia/ -- 3SBio Inc. ( SSRX),("3SBio" or "the Company"), ... marketing,biopharmaceutical products, today announced its unaudited financial results,for the fourth quarter and ... Full Year 2009 Financial Highlights:, -- Total net ...
Cached Biology Technology:Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 2Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 243SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 253SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 26
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... protecting us from diseases, but how does it do ... before dendritic cells move to the lymph nodes they ... much faster. Immature dendritic cells patrol the tissues in ... undergo a rigorous maturation process. During this maturation the ...
... St. Jude Children,s Research Hospital have discovered that a ... its identity that it requires the constant expression of ... The researchers showed that Prox1 acts as a two-way ... type of cell, called a lymphatic endothelial cell (LEC). ...
... of propensities acquired in the womb) reveals that consuming ... may significantly affect breast cancer outcomes for a mother,s ... Boston University is the first to link choline consumption ... first to identify possible choline-related genetic changes that affect ...
Cached Biology News:Immune cells reveal fancy footwork 2Reprogrammable cell type depends on a single gene to keep its identity 2Eating eggs when pregnant affects breast cancer in offspring 2
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: